GRI
GRI Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.79
+21.83%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.6x
Market Cap
$6.10M
MomentumView details →
1D Return
+21.83%
YTD Return
−62.08%
RSI (14)
73.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.6x
Market Cap
$6.10M
RSI (14)
73.3
MomentumView details →
1D Return
+21.83%
YTD Return
−62.08%
SummaryUpdated Jun 1, 2026
GRI Bio, Inc. (NASDAQ:GRI) is a clinical-stage biopharmaceutical company founded in 2009 and headquartered in La Jolla, California. Originally established as Glycoregimmune, Inc., the company went public in February 2021 and focuses on developing novel therapeutic treatments for inflammatory, fibrotic, and autoimmune diseases. As a clinical-stage biotechnology firm, GRI Bio operates without generating product revenue, instead relying on research and development activities to advance its pipeline of experimental drug candidates through various phases of clinical trials.
Similar companies
Latest newsMore news →
GRI Bio announced that three abstracts and an oral presentation highlighting data from its Phase 2a GRI-0621-IPF-02 study have been selected for presentation at the 2026 European Respiratory Society Congress in Barcelona, Spain.11d agoThe U.S. Food and Drug Administration granted Orphan Drug Designation to GRI Bio's drug GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis.78d ago